StoxVijaya Diagnostic Centre vs NATCO Pharma: share price & financials comparison
NSE: VIJAYA vs NATCOPHARM · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Vijaya Diagnostic Centre vs NATCO Pharma at a glance
Vijaya Diagnostic Centre (VIJAYA) has a market capitalisation of ₹15,126 Cr, against ₹14,445 Cr for NATCO Pharma (NATCOPHARM). Over the past year Vijaya Diagnostic Centre has returned +45.8%, compared with -2.5% for NATCO Pharma. On valuation, NATCO Pharma trades at a lower P/E of 12.6 versus 74.3. Vijaya Diagnostic Centre earns a higher return on equity (19.3% vs 12.4%). Vijaya Diagnostic Centre comes out ahead on profitability, growth, momentum and technicals. NATCO Pharma comes out ahead on size and valuation. Across the scored metrics below, Vijaya Diagnostic Centre leads on 11 and NATCO Pharma on 5. On StoxGud's 10-point checklist, Vijaya Diagnostic Centre scores 9/10 and NATCO Pharma scores 4/10.
| Metric | Vijaya Diagnostic Centre | NATCO Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹15,126 Cr | ₹14,445 Cr |
| Revenue (latest FY) | ₹814 Cr | ₹4,078 Cr |
| Net profit (latest FY) | ₹173 Cr | ₹1,418 Cr |
| Valuation | ||
| P/E | 74.3 | 12.6 |
| P/B | 14.31 | 1.57 |
| Dividend yield | 0.14% | 0.62% |
| Profitability | ||
| Return on equity | 19.3% | 12.4% |
| Net profit margin | 22.4% | 32.8% |
| Operating margin | 43.1% | 30.2% |
| Growth | ||
| Revenue growth (YoY) | +26.7% | -44.7% |
| Net profit growth (YoY) | +37.4% | -57.0% |
| Revenue CAGR (multi-year) | +15.2% | +14.7% |
| Financial health | ||
| Debt to equity | 0.00 | 0.08 |
| Momentum | ||
| 1-month return | +0.4% | -0.4% |
| 1-year return | +45.8% | -2.5% |
| 3-year CAGR | +35.9% | +2.6% |
| 5-year CAGR | +21.1% | -1.5% |
| 10-year CAGR | — | +3.3% |
| Distance from 52W high | -6.5% | -33.1% |
| Technicals | ||
| RSI (14) | 67 | 62 |
| Price vs 200-day avg | +18.0% | -13.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Vijaya Diagnostic Centre | NATCO Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 9/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Vijaya Diagnostic Centre or NATCO Pharma?
Vijaya Diagnostic Centre has a market cap of ₹15,126 Cr and NATCO Pharma has a market cap of ₹14,445 Cr as of 06 Nov 2026.
Which has a lower P/E, Vijaya Diagnostic Centre or NATCO Pharma?
NATCO Pharma has the lower P/E: Vijaya Diagnostic Centre trades at 74.3 and NATCO Pharma at 12.6.
Which gave better returns in the last year, Vijaya Diagnostic Centre or NATCO Pharma?
Vijaya Diagnostic Centre did better: Vijaya Diagnostic Centre returned +45.8% and NATCO Pharma returned -2.5% over one year.
Is Vijaya Diagnostic Centre or NATCO Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Vijaya Diagnostic Centre scores 9/10 and NATCO Pharma scores 4/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.